Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Metyrapone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Esteve Healthcare
Deal Size : $294.2 million
Deal Type : Divestment
Perrigo Receives Offer To Divest HRA Pharma Rare Diseases Business
Details : Esteve expands its rare disease portfolio through divestment, including Metopirone (metyrapone) for treating symptoms of Cushing's syndrome by lowering cortisol levels.
Brand Name : Metopirone
Molecule Type : Small molecule
Upfront Cash : $203.3 million
April 25, 2024
Lead Product(s) : Metyrapone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Esteve Healthcare
Deal Size : $294.2 million
Deal Type : Divestment
Lead Product(s) : Ulipristal Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Perrigo Company plc
Deal Size : Undisclosed
Deal Type : Acquisition
Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma
Details : HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).
Brand Name : ellaOne
Molecule Type : Small molecule
Upfront Cash : $2,100.0 million
September 08, 2021
Lead Product(s) : Ulipristal Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Perrigo Company plc
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
